AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Recent Alzheimer's disease dynamics are a positive for Biogen's Leqembi - analyst
March 11, 2024 2:01 PM EDTOn Monday, Oppenheimer reiterated its Outperform rating and $290 price target for Biogen (NASDAQ: BIIB) amid recent developments in the Alzheimer's Disease (AD) treatment landscape. The competitive dynamics have shifted significantly, potentially benefiting Biogen's AD drug, Leqembi, which is developed in partnership with Eisai. Eisai has reported progress on multiple fronts for Leqembi, while a competitor, Eli Lilly, announced an unexpected delay for its AD drug,... More
